Recent Company News

• 08:00 AM ET Sep 11, 2025
  

  Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy

• 08:00 AM ET Aug 01, 2025
  

  Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market

• 06:08 PM ET Dec 05, 2023
  

  Kazia Therapeutics closes registered direct offering to raise $2M at $0.45/ADS through HC Wainwright

• 08:07 AM ET Dec 01, 2023
  

  Kazia Therapeutics announces $2M registered direct offering through HC Wainwright ($0.56, 0.00)

• 07:25 AM ET Nov 29, 2023
  

  Kazia Therapeutics signs LOI to grant rights for development, commercialization of paxalisib outside of oncology

• 07:11 PM ET Nov 14, 2023
  

  Kazia Therapeutics will be removed from the Official List at the close of trading today, 15-Nov (A$0.08, 0.00)

• 04:24 PM ET Nov 13, 2023
  

  The Bank of New York Mellon increases stake in Kazia Therapeutics to 48.36% from 37.39% - Form 604 (A$0.08, 0.00)

• 01:40 AM ET Nov 13, 2023
  

  Trading suspended in Kazia Therapeutics to facilitate removal from the official list of ASX (A$0.08, 0.00)

• 07:49 PM ET Nov 05, 2023
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday